Literature DB >> 22654923

A new paradigm for clinical trials in antibiotherapy?

Kevin B Laupland1, David N Fisman.   

Abstract

Year:  2011        PMID： 22654923      PMCID： PMC3142591          DOI： 10.1155/2011/412857

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  39 in total

1.  Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland.

Authors:  Massimo Filippini; Giuliano Masiero; Karine Moschetti
Journal:  Health Policy       Date:  2005-11-10       Impact factor: 2.980

2.  Trials: the next 50 years. Large scale randomised evidence of moderate benefits.

Authors:  R Peto; C Baigent
Journal:  BMJ       Date:  1998-10-31

3.  Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

Authors:  Jyh-Ming Liou; Jaw-Town Lin; Chi-Yang Chang; Mei-Jyh Chen; Tsu-Yao Cheng; Yi-Chia Lee; Chien-Chuan Chen; Wang-Huei Sheng; Hsiu-Po Wang; Ming-Shiang Wu
Journal:  Gut       Date:  2010-05       Impact factor: 23.059

4.  Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin.

Authors:  Isao Ito; Seizo Kadowaki; Naoya Tanabe; Akane Haruna; Masahito Kase; Yoshiro Yasutomo; Mitsuhiro Tsukino; Asako Nakai; Hisako Matsumoto; Akio Niimi; Kazuo Chin; Satoshi Ichiyama; Michiaki Mishima
Journal:  Pulm Pharmacol Ther       Date:  2010-06-02       Impact factor: 3.410

5.  A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Authors:  Edward W Hook; Frieda Behets; Kathleen Van Damme; Noro Ravelomanana; Peter Leone; Arlene C Sena; David Martin; Carol Langley; Linda McNeil; Mark Wolff
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

6.  High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Authors:  Qinjuan Sun; Xiao Liang; Qing Zheng; Wenzhong Liu; Shudong Xiao; Weiqi Gu; Hong Lu
Journal:  Helicobacter       Date:  2010-06       Impact factor: 5.753

7.  Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.

Authors:  L Gómez; C Estrada; I Gómez; M Márquez; C Estany; J M Martí; R Bastús; L Cirera; S Quintana; J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-27       Impact factor: 3.267

8.  Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.

Authors:  P Judlin; Q Liao; Z Liu; P Reimnitz; B Hampel; P Arvis
Journal:  BJOG       Date:  2010-08-18       Impact factor: 6.531

9.  Statin use and mortality within 180 days after bacteremia: a population-based cohort study.

Authors:  Reimar W Thomsen; Heidi H Hundborg; Søren P Johnsen; Lars Pedersen; Henrik T Sørensen; Henrik C Schønheyder; Hans-Henrik Lervang
Journal:  Crit Care Med       Date:  2006-04       Impact factor: 7.598

10.  A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.

Authors:  M Heystek; J D C Ross
Journal:  Int J STD AIDS       Date:  2009-10       Impact factor: 1.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.